United States FDA Approves NM8074 (Ruxoprubart) IND for Treating Dermatomyositis (DM): A Chronic Inflammatory Disorder of the Skin
--- The United States FDA Approves the Initiation for Phase II Efficacy…
Tag: dermatomyositis
--- The United States FDA Approves the Initiation for Phase II Efficacy…
